The above findings suggested that MGMT promoter methylation has predictive value for both IDH-mutant and IDH-wildtype GBM cases, but the optimal cutoff value for IDH-mutant GBM is higher than that for IDH-wildtype GBM. The gene discussed is IDH2; the disease is glioblastoma.